- Home
- TLSA vs APLT Comparison
TLSA vs APLT Comparison
Compare TLSA & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- APLT
- Stock Information
- Founded
- TLSA 2013
- APLT 2016
- Country
- TLSA United Kingdom
- APLT United States
- Employees
- TLSA N/A
- APLT N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- APLT Health Care
- Exchange
- TLSA Nasdaq
- APLT Nasdaq
- Market Cap
- TLSA 187.0M
- APLT 44.0M
- IPO Year
- TLSA 2000
- APLT 2019
- Fundamental
- Price
- TLSA $1.44
- APLT $0.42
- Analyst Decision
- TLSA
- APLT Buy
- Analyst Count
- TLSA 0
- APLT 7
- Target Price
- TLSA N/A
- APLT $6.10
- AVG Volume (30 Days)
- TLSA 193.5K
- APLT 2.7M
- Earning Date
- TLSA 07-22-2025
- APLT 08-06-2025
- Dividend Yield
- TLSA N/A
- APLT N/A
- EPS Growth
- TLSA N/A
- APLT N/A
- EPS
- TLSA N/A
- APLT N/A
- Revenue
- TLSA N/A
- APLT $265,000.00
- Revenue This Year
- TLSA N/A
- APLT $1,768.13
- Revenue Next Year
- TLSA N/A
- APLT $292.85
- P/E Ratio
- TLSA N/A
- APLT N/A
- Revenue Growth
- TLSA N/A
- APLT N/A
- 52 Week Low
- TLSA $0.63
- APLT $0.30
- 52 Week High
- TLSA $1.91
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- TLSA 46.42
- APLT 60.22
- Support Level
- TLSA $1.43
- APLT $0.32
- Resistance Level
- TLSA $1.81
- APLT $0.36
- Average True Range (ATR)
- TLSA 0.09
- APLT 0.04
- MACD
- TLSA -0.02
- APLT 0.01
- Stochastic Oscillator
- TLSA 10.53
- APLT 88.67
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.